TL;DR: Green Thumb Industries (OTCQX: GTBIF) enters its August 4, 2026 earnings window as the only major U.S. multi-state operator with a sustained profitability track record, reporting $0.51 diluted EPS on trailing twelve-month revenue of $1.2 billion. The stock trades at $7.60, representing a significant discount to the analyst consensus target of $15.67, with a trailing P/E ratio of 14.90 that stands in sharp contrast to sector peers still navigating net losses. The convergence of an accelerating federal rescheduling timeline and demonstrated profitability positions GTBIF as a central name heading into Q2 2026 earnings season.
Market Analysis
Green Thumb Industries presents one of the stronger fundamental profiles in the U.S. cannabis sector heading into Q2 2026 earnings season. The company closed Q1 FY2026 with revenue of $300.19 million, a figure that places it among the top-tier MSOs by topline scale while its $8.24 million quarterly net income separates it from the majority of operators still burning cash reserves.
Trailing twelve-month financials paint a picture of operational maturity that is rare in the cannabis space: $1.2 billion in annual revenue, a profit margin of 10.14%, a return on equity of 6.63%, and diluted EPS of $0.51. Enterprise value stands at $1.95 billion versus revenue of $1.2 billion, yielding an EV/Revenue multiple of 1.63 — a conservative valuation for a profitable business in a sector still viewed as distressed by many institutional allocators. The EV/EBITDA of 3.85 is particularly notable: the market is ascribing near-distressed-asset multiples to a company generating positive trailing net income.
The 52-week trading range of $5.29 to $10.43 reflects the high-beta nature of cannabis equities broadly, but GTBIF has demonstrated relative resilience. The current price of $7.60 represents a 44% premium to the 52-week low and sits roughly midway through the annual range. With a five-year monthly beta of 0.93 against the S&P/TSX composite, GTBIF behaves less like a speculative cannabis name and more like a mid-cap growth company navigating a transitional regulatory environment.
One-year total return through early July 2026 stands at 38.18%, outpacing the S&P/TSX composite’s 30.49% over the same period. The year-to-date return of 5.71% lags the broader index, suggesting that sector-level rescheduling uncertainty has weighed on near-term price action despite solid underlying fundamentals.
The analyst consensus target of $15.67 implies approximately 106% upside from current levels, spanning $10.00 on the low end to $20.00 on the high end. Wedbush maintains an Outperform rating with a $16.00 price target. The forward P/E of 47.17 reflects consensus estimates anticipating near-term earnings compression before a re-acceleration driven by regulatory tailwinds — specifically, 280E normalization under Schedule III reclassification.
Investors tracking the broader cannabis sector can review real-time performance data and sector benchmarks through our cannabis stock tracker.
Regulatory and Market Context
The setup entering GTBIF’s August 4 earnings date includes a federal rescheduling backdrop that remains the sector’s most significant pending catalyst. The DEA’s marijuana rescheduling process — moving cannabis from Schedule I to Schedule III under the Controlled Substances Act — has advanced to the hearing phase, with the Trump administration’s stated support adding institutional momentum to a timeline that has frustrated markets for over two years.
Schedule III reclassification carries direct implications for Green Thumb’s tax profile. Under current IRS Section 280E rules, cannabis operators cannot deduct standard business expenses, creating effective tax rates that would be punitive in any other industry. GTBIF, despite operating at GAAP profitability, carries a disproportionate 280E burden that would substantially expand its bottom line in a post-reclassification environment. The company’s management has consistently cited 280E normalization as a primary margin expansion lever that exists independently of same-store sales growth.
The Q2 2026 earnings call will be closely monitored for three key vectors: (1) the company’s same-store sales trajectory against a backdrop of adult-use market maturation in core states including Illinois, Pennsylvania, and New Jersey; (2) any updates to capital allocation strategy as rescheduling timelines crystallize; and (3) cost structure management in states where cannabis pricing compression has eroded per-gram profitability across the MSO tier.
Conclusion
Green Thumb Industries heads into its August 4, 2026 earnings window as the benchmark profitable MSO in the U.S. cannabis sector, trading at multiples that continue to reflect significant market skepticism relative to analyst consensus targets. The convergence of an accelerating federal rescheduling timeline and a demonstrated profitability track record positions GTBIF as a central holding for institutional investors reappraising cannabis sector exposure ahead of what could be the most consequential regulatory window since adult-use legalization began reshaping state markets. With a 52-week high of $10.43 still within reach and a consensus target of $15.67, the August earnings release and any rescheduling procedural updates before year-end represent the near-term catalysts most likely to drive price action in either direction.